solute carrier family 25 member 36Genealiases: HHF8 · PNC2
Q-omics provides the consensus-scored SLC25A36 profile across patient tissues and cancer cell-line models. SLC25A36 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SLC25A36 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, SLC25A36 protein abundance shows 24,218 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight ACC, HNSC, and UCEC as cancer lineages where SLC25A36 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC25A36 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC25A36 survival associations across molecular data types. SLC25A36 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC25A36 RNA expression–survival associations across cancer types. High SLC25A36 expression shows unfavorable associations in ACC, LUSC and MESO, but favorable associations in SKCM, LAML and CHOL. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SLC25A36 RNA expression.
This table summarizes SLC25A36 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC25A36. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC25A36 shows lower tumor expression in THCA, LUAD and KIRP and higher tumor expression in HNSC, BLCA and CHOL. The HNSC box plot shows higher SLC25A36 RNA expression in tumor versus normal tissue (log2 FC = +1.399, t-test p < 0.001).
This table shows molecular features associated with SLC25A36 in patient tissues and cancer cell lines. In patient samples, SLC25A36 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC25A36 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BREAST.
